Veneta Tablet 50 mg contains Venetoclax 50 mg, a targeted oral anticancer medication designed to treat hematologic malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Venetoclax is a BCL-2 inhibitor, which works by promoting programmed cell death (apoptosis) in cancer cells, leading to reduced tumor burden and improved patient outcomes.

Veneta Tablet 50 mg is often used as a starting or titration dose during gradual dose escalation to reduce the risk of tumor lysis syndrome (TLS), a potentially serious complication during early treatment. It is an essential therapy for patients with relapsed, refractory, or high-risk CLL, including those with 17p deletion or resistance to previous treatments.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Venetoclax 50 mg per tablet

Mechanism of Action

Venetoclax, the active ingredient in Veneta Tablet 50 mg, exerts its effect by:

1. Selective inhibition of BCL-2 protein – BCL-2 is a protein that prevents cancer cell death; Venetoclax blocks this protein, restoring the apoptosis pathway.

2. Induction of apoptosis in malignant cells – Leads to rapid death of cancerous lymphocytes.

3. Tumor burden reduction – Effective in reducing cancer cell counts in the blood, bone marrow, and lymph nodes.

4. Synergistic effect with other therapies – Can be combined with monoclonal antibodies or chemotherapy to enhance antitumor activity.

5. Targeted therapy – Limits damage to normal cells, providing a safer alternative compared to conventional chemotherapy.

This precise mechanism ensures effective cancer control while reducing side effects.

Indications

Veneta Tablet 50 mg is indicated for:

• Chronic lymphocytic leukemia (CLL) – Especially in patients with 17p deletion or relapsed/refractory disease

• Small lymphocytic lymphoma (SLL) – For adult patients not responding to prior therapy

• Combination therapy – Can be used with rituximab or obinutuzumab for first-line or relapsed treatment

• High-risk hematologic malignancies – Providing targeted therapy for patients with aggressive disease features

It is intended for use in adult patients under strict medical supervision.

Dosage and Administration

• Starting dose: 50 mg once daily as part of a dose ramp-up schedule

• Administration: Swallow the tablet whole with water; may be taken with or without food

• Dose escalation: Gradual increase to the recommended therapeutic dose (up to 400 mg daily) to minimize the risk of TLS

• Monitoring: Regular blood tests to monitor white blood cell counts, renal function, and electrolytes during initial therapy

• Duration: Continued until disease progression or unacceptable toxicity occurs

Benefits

• Provides effective targeted therapy for CLL and SLL

• Reduces tumor burden in blood, bone marrow, and lymph nodes

• Useful for relapsed, refractory, or high-risk patients

• Can be combined with other therapies for enhanced treatment efficacy

• Oral administration allows convenient outpatient treatment

Precautions

• Monitor for tumor lysis syndrome (TLS), especially during dose escalation

• Use with caution in patients with renal or hepatic impairment

• Pregnancy and breastfeeding: Venetoclax is contraindicated due to potential fetal harm

• Avoid abrupt discontinuation to maintain therapeutic efficacy

• Check for drug interactions with CYP3A inhibitors, inducers, and other medications

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects:

• Nausea, vomiting, diarrhea

• Fatigue and headache

• Low blood cell counts (neutropenia, anemia, thrombocytopenia)

Serious side effects:

• Tumor lysis syndrome (TLS)

• Severe infections due to neutropenia

• Liver enzyme elevations

• Allergic reactions in rare cases

Immediate medical attention is required for severe bleeding, kidney issues, or infections.

Storage

• Store below 25°C in a cool, dry place

• Protect from light and moisture

• Keep tablets in the original blister pack until use

• Keep out of reach of children

Veneta Tablet 50 mg provides a targeted and safe starting dose for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, ensuring gradual, controlled therapy to reduce tumor burden while minimizing potential side effects.